07:52 AM EDT, 06/24/2025 (MT Newswires) -- InMed Pharmaceuticals ( INM ) said Tuesday that new preclinical data show that INM-901 "significantly reduces" inflammation in ex vivo models of neuroinflammation.

The data demonstrate a statistically significant reduction of pro-inflammatory cytokines and levels of inflammasome marker NLRP3, supporting the potential of INM-901 as a therapeutic candidate for Alzheimer's disease, the company said.

InMed's shares climbed 96% in recent Tuesday premarket activity.